Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): A multinational open-label randomised trial

Abstract

ABSTRACT Thrombophilias are acquired or genetic predispositions to venous thromboembolism (VTE), which occurs more often in pregnant than in nonpregnant women. Placenta-mediated complications, including preeclampsia, small-for-gestational-age (SGA) infant, placental abruption, or pregnancy loss, are also more common in women with thrombophilia. Whether pregnant women with thrombophilia should receive antepartum thromboprophylaxis remains unclear. Low-molecular-weight heparin (LMWH) is the drug of choice in pregnancy for women who require anticoagulation, as it does not cross the placenta and has a low risk of major bleeding, heparin-induced thrombocytopenia, and heparin-induced osteoporosis...